Amorepacific Corporation

Wonkyung Cho

Kwanghyun Shin

Byoung Young Woo

Miyoung Park

Jong Hwa Roh

Joonho Choi

Jaehong Park

Youngho Park

Kyoungmi Jung

Eunsil Park

Kiwha Lee

Gyeyoung Choi

Jihae Lee

Min Soo Kim

Yong Deog Hong

Jinoh Chung

Chang Soon Choi

Hyunjin Nam

Young-Ho Park

Chan Woong Park

Ki-Wha Lee

Su Hwan Kim

Wanki Kim

Kwang-Hyun Shin

Changyong Moon

Eun Sol Ha

The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

GABA complex composition

One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.

Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof

One aspect of the present disclosure relates to a sol-gel composition enabling reversible sol-gel transition and, more specifically, to a sol-gel composition of which the viscosity changes by external physical force so that reversible sol-gel transition is performed.

Topical sol-gel composition for the treatment of dermatitis

Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.

Composition for preventing or treating atopic dermatitis

Shown are a particulate processed product of tea and a method for preparing the same. The particulate processed product of tea has a sphericity Svalue of a particle corresponding to 10% cumulative subdistribution in cumulative distribution measured for the sphericity of tea particles of 0.68 or greater. The processed product of tea is convenient to drink because it is readily wetted and dispersed in water. In addition, it can be easily packaged and used due to a low angle of repose and thus excellent flowability.

Processed products of tea and method for manufacturing the same

The present disclosure shows a particulate processed product of tea with quick dispersibility in water and a method for manufacturing a particulate processed product of tea. The processed product of tea comprises 20% by weight or less of fine powders having a particle diameter of 75 &#x3bc;m or less based on the total weight of the tea particles. The manufacturing method comprises the step of manufacturing tea particles using a fluid-bed rotor granulator having a rotor disc. The processed product of tea has quick wettability and dispersibility in water and thus is easy to drink. Also, the processed product of tea has a low angle of repose and thus has excellent flowability, so that it is easy to pack and use.

Processed products of tea with quick dispersibility in water and method for manufacturing processed products of tea

Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)&#x2014;N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.

Composition for preventing or treating sleep disorders

The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O'-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O&#x2032;-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives

Growing community of inventors

Yongin-si, South Korea

Wonkyung Cho